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Abstract: In recent years, the progress of science and medicine greatly has influenced human life
span and health. However, lifestyle habits, like physical activity, smoking cessation, moderate alcohol
consumption, diet, and maintaining a normal body weight represent measures that greatly reduce
the risk of various diseases. The type of diet is very important for disease development. Numerous
epidemiological clinical data confirm that longevity is linked to predominantly plant-based diets
and it is related to a long life; whereas the western diet, rich in red meat and fats, increases the risk
of oxidative stress and thus the risk of developing various diseases and pre-aging. This review is
focused on the bioavailability of polyphenols and the use of polyphenols for the prevention of prostate
diseases. Special focus in this paper is placed on the isoflavonoids and flavan-3-ols, subgroups of
polyphenols, and their protective effects against the development of prostate diseases.
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1. Introduction
1.1. Human Evolution and Diet
It seems that Homo sapiens have not yet fully adapted to the meat diet. Namely, millions of years
ago all human ancestors were herbivores. It is evidenced by anatomical features and evolutionary
evidence, as well as by the diet of the closest human relatives, hominids [1].
Only some 15,000 years ago, man began to build settlements, raise livestock, and eat the meat of
domestic animals. The transition to meat foods was probably related to a sharp increase in the number
of free radicals in the cells and oxidative stress occurrence. At the same time, man reduced plant intake,
from some 3000 species to only 20–30 species; the number of plant foods rich in antioxidants, vitamins,
and polyphenols also reduced. Coffey believes that this change in diet brought an explosive jump in the
occurrence of prostate cancer and breast cancer [2]. Today, there is a very noticeable difference between
the high incidence of these two cancers in Europe, America, and Australia and the low incidence in
regions where plant-based nutrition is prevalent, such as in Asia and the Far East. Increasing human
lifespan is another factor that allows the cumulative effect of carcinogens. Namely, in the Neolithic
period, the average lifespan was about 20 years, and today, it is 70–80 years [3].
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How is the protective effect of plant foods on the human body explained? The basis of plant and
animal cell functioning are similar biochemical processes, and are understandable, given the common
origin of plants and animals. Namely, life on Earth existed for 3.5 billion years, and animals separated
from plants about 670 million years ago [4]. The first animals lost their ability of photosynthesis and
the synthesis of a large number of antioxidants, which they had to compensate by eating plants.
1.1.1. Oxygen, Reactive Oxygen Species, and Oxidative Stress
Oxygen is an element without which life on Earth as we know it today would be impossible.
Oxygen is the driver of an incalculable number of oxidative chemical reactions that occur in the entire
living and non-living world. The first amounts of oxygen in the ocean began to produce cyanobacteria
through photosynthesis, about 2.7 billion years ago, while significant oxygen production began
2.5 billion years ago, when oxygen was released from the sea and entered the atmosphere. The large
amount of oxygen enormously increased the energy sources necessary for living beings, which led to
the expansion of evolution [5].
The first terrestrial plants appeared 410 million years ago, some 100 million years before the
appearance of the first terrestrial herbivores [6,7]. These plants found themselves in an environment
rich in solar energy, which allowed more intense photosynthesis, but also the production of large
quantities of reactive oxygen species (ROS). Plant cells used ROS to defend against pathogens; however,
as an adaptation to the excessive and potentially dangerous amounts of ROS, the plants began to
increase production of antioxidants, vitamins, and polyphenols.
1.1.2. Generation of Reactive Oxygen Species in Cells
In all aerobic organisms, the energy for biological functions is generated in the mitochondria.
As byproducts, ROS are also produced on a daily basis; the most important ROS are hydrogen peroxide
(H2O2), hypochlorous acid (HClO), and the free radicals: hydroxyl radical (OH−) and superoxide
anion (O2−). The largest producers of ROS are NADPH oxidase enzymes, which are found on the cell
membrane, mitochondria, and endoplasmic reticulum.
Mitochondria convert the energy into a usable form, adenosine triphosphate (ATP). The process
of ATP formation involves the transport of hydrogen ions (H+) through the inner membranes of the
mitochondria, by the electron transport chain process. During this chain of reactions, electrons undergo
a series of proteins via oxidative-reduction reactions; each protein in the series that receives an electron
has a greater reduction potential than the previous one. The ultimate destination of the electrons
in this chain is the oxygen molecule, O2. Under normal circumstances, O2 is reduced and produces
water, H2O. However, in 0.1–2% of electrons passing through the chain, O2 is reduced prematurely
and incompletely into radical superoxide, O2. Hydrogen peroxide, H2O2, is formed from superoxide,
which leaks from the mitochondria. The enzymes catalase and superoxide dismutase convert H2O2 to
oxygen and superoxide to H2O2, from which H2O is formed. However, this conversion is not 100%
efficient and a certain amount of H2O2 lags in the cell. If too much damage occurs in the mitochondria,
programmed death, apoptosis, occurs in the cell. The Bcl-2 protein, located on the surface of the
mitochondria, detects damage and activates a class of protein called Bax, which drill holes in the
mitochondrial membrane and leads to the leakage of the protein of the electron transport chain, called
cytochrome C. After that, the released cytochrome C begins a series of reactions leading to the cleavage
of proteins in the mitochondrial membrane and its disintegration [8].
ROS is considered—when formed as by-products of normal oxygen metabolism—to have an
important role in cell signaling and homeostasis. Small, normal amounts of ROS generated within
a cell initiate a lot of important processes, such as regulation of apoptosis, induction of various
defense genes, release of ROS from platelets during hemostasis, leukocyte attraction, activity during
an inflammatory response, etc. Under normal circumstances, the cell is able to counteract the effects of
smaller amounts of ROS by producing antioxidant molecules. However, if the amount of ROS exceeds
the antioxidant capacity of the cell over time, the genetic material and other parts of the cell can be
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damaged. The cumulative effect of excessive amounts of ROS is called oxidative stress (OS); OS is
associated with the aging and development of various diseases. There is evidence that animals that
have been genetically engineered to remove antioxidant enzymes have a shorter life span [9].
One of the main causes of mutations is DNA oxidation. It is estimated that the normal daily
endogenous production of ROS in a single cell modifies about 20,000 DNA bases [10]. However, during
OS, the cell is unable to eliminate a large amount of ROS; ROS then activates a variety of transcription
factors, leading to the synthesis of proteins that control inflammation, survival, proliferation, and
invasiveness of tumor cells. It is considered for ROS to have a similar effect on normal and malignant
cells: Low levels of ROS favorably affect the survival of the malignant cell, while a high level of ROS
suppresses tumor growth and induces apoptosis. Ionizing radiation and cytostatics increase ROS
formation [11].
Antioxidants react with ROS by self-oxidizing and thus reducing the possibility of oxidative
damage to cellular organelles. The function of the antioxidant system is not to completely remove the
oxidants, but to maintain them at the optimal level. Antioxidants are generally reducing agents, such
as thiols, ascorbic acid or polyphenols. Human cells can produce some antioxidants on their own, like
superoxide dismutase, catalase, and glutathione peroxidase, while some have to be ingested through
food, like vitamin E, vitamin C, polyphenols, carotenoids, etc. [12]. When vitamins A, C, and E were
identified as antioxidants, the study of them began in the biology of living beings. The early research,
dealing with the way that vitamin E prevented peroxidation of lipids, represented an introduction into
antioxidant studies.
2. Prostate and Prostate Diseases
The prostate is an organ that belongs to the accessory of the male reproductive organs. In all
mammals, the prostate is involved in the production of seminal plasma, which serves as a medium for
the transport and nourishment of sperms. The prostate function is controlled by steroid hormones and
its structure is basically similar in all mammals. In most primates, the prostate is composed of two
parts, the cranial and caudal prostate; in humans, these two parts are located in one compact organ
and correspond to the central zone (CZ) i.e., peripheral zone (PZ) [13].
The diseases of the prostate are rare in mammals. Benign prostatic hyperplasia (BPH) occurs in
humans, chimpanzees, and dogs. Prostate cancer (PCa) is extremely rare in all mammals, including
chimpanzees and apes. The low incidence of PCa in hominids is primarily explained by the fact that
they are obligate herbivores [14].
2.1. Prostate Physiology
The prostate structure is made up of connective stroma and epithelial cells. The stroma consists
of the basic substance, axons of nerve cells and stromal cells, fibroblasts, endothelial cells, and
smooth muscle cells. The prostate epithelium is composed of secretory, neuroendocrine, basal, and
intermediate cells.
The most important physiological functions of the prostate are secretory and hormonal.
The prostate synthesizes and secretes numerous non-peptide substances, such as polyamines,
cholesterol, lipids, citrates, and zinc. Citrates and zinc are found in the prostate at a much higher
concentration than in other organs and tissues [15]. The most important proteins in the prostatic
secretion are prostate-specific antigen (PSA), glandular kallikrein (hK2), and prostatic acid phosphatase
(PAP). The most important enzyme in the semen fluid, PSA, exerts its physiological function only in
the vagina, where it cleaves the proteins of the seminal coagulum and thus enables the active mobility
of the sperms. PSA molecules constantly leak from the prostatic acini in the urethra, wherefrom they
are flushed during the urination act [16–18].
The hormonal function of the prostate is related to the intracrine and paracrine activity.
Paracrine factors, acting from neighboring cells, are tissue growth factors (GFs), small peptide molecules
that stimulate and/or inhibit cell division and differentiation. The balance between proliferation and cell
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death is dictated by the complex interactions between GFs and steroid hormones. Fibroblast GF (FGF),
vascular endothelial GF (VEGF) and insulin-like GF (IGF) are thought to promote cell proliferation
in BPH, and DHT enhances their action [19]. Transforming GF-β (TGF-β1) inhibits epithelial cell
proliferation while stimulating fibroblast mitosis. Increased expression of TGF-β1 on stromal cells is
associated with an increase in the stromal compartment [20].
2.2. Sex Hormones in Prostatic Tissue
The most important serum androgen, testosterone (T), acts as a prohormone: In prostate cells,
most of T is converted to potent DHT by the action of enzyme 5-alpha reductase (5-αR); a number of T
molecules are converted to estradiol (E2) by the action of enzyme aromatase. Estrogens act on the
human prostate via interaction with two receptor subtypes, ERα and ERβ. The dominant estrogen
receptor in the prostate is ERβ, which is found both in the stroma and in the epithelium (Figure 1),
whereas ERα is found primarily in the stroma. In general, ERα stimulation stimulates cell proliferation,
whereas ERβ stimulation counteracts these effects [21]. The activation of ERβ influences azote oxide
metabolism (NO) and thus leads to vasodilatation.
Growth factors (GF) are small peptide molecules that stimulate, and sometimes, inhibit the
division process and cell differentiation, by activating cell receptors for GF. The balance between
proliferation and cell death dictate the complex interactions between GF and steroid hormones. It is
considered that FGF (fibroblast GF), VEGF (vascular endotel GF) and IGF (insulin-similar GF) stimulate
cell proliferation with BHP, and DHT increases their effect. The most important factor is the interaction
of stroma and epithelium is FGF-7 [19]. The factor of TGF-β1 (transforming GF-β) performs a line of
important functions: It stimulates mitosis with fibroblast and inhibits proliferation of epithelium cells.
The increased effect of TGF-β1 stroma cells is connected to the increase of the stroma section [20].
There are numerous reciprocal reactions between the stroma and the epithelium, called the
stroma–epithelial interaction; this process begins during embryonic development, continues during
prostate development, and lasts throughout adulthood and old age [22].
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2.3. Prostate Diseases
Prostate diseases are of great importance in modern men: BPH is ranked fourth in the most
common chronic diseases and eighth in the cost of their treatment. Prostate cancer (PCa) is the fourth
most common cancer in the world and the second most common cancer in men. In the USA, PCa is the
most common malignancy in men and accounts for 27% of all cancers [23,24]. Prostatitis is the third
most common urological diagnosis with people of 50 years and older, after BHP and PCa, it is the most
common urological diagnosis with people younger than 50 years.
2.4. Benign Prostatic Hyperplasia
By definition, BPH is a histologic diagnosis, which involves the uncontrolled proliferation of the
prostatic stroma and epithelium and enlargement of the prostate gland. Lower urinary tract symptoms
(LUTS) very often accompany BPH and enlargement of the prostate and they gradually worsen over
time. The most frequent LUTS are very difficult urination and the feeling of incomplete bladder
vacating, frequent urination, night urination, etc. A complete discontinuation of an urination process
and a bladder stone are indications to have BPH surgery.
Global BPH prevalence is 26%. The prevalence increases with aging: After 50 years of age, it
is 50%, and at the age of 60, 60% of men have BPH with LUTS. The prevalence of BPH is higher in
Chinese people living in the USA than in Chinese people in China [25–27]. These facts are in favor of
the theory that for BHP to appear, lifestyle and dieting, not only genetic heritage, are of importance.
Risk factors for BPH development are low physical activity, obesity and metabolic syndrome.
The familial form of BPH is present in 50% of patients under 60 years of age who underwent simple
prostatectomy [28]. The presence of androgens during the development of the prostate, puberty, and
aging represents the fundamental condition for the development of BPH.
However, the role of androgens in the onset of BPH is not entirely clear, as BPH develops in
elderly people with normal or low serum androgen levels. However, DHT levels in prostate tissue
remain high [29,30]. Pejcˇic´ et al. proved that T and DHT accumulate in the prostatic stroma in BPH and
that there is a linear correlation between T and DHT concentration in the tissue and prostate size [31].
Estrogen accumulation has also been demonstrated in prostatic tissue [32,33].
2.5. Prostate Cancer
Prostate cancer (PCa) is generally diagnosed in men over 65, and very rarely in the ones under
50. Today, PCa is the most commonly diagnosed cancer in men in America, Europe, Australia, and
Sub-Saharan Africa [34,35]. In the USA, the highest PCa incidence is found in Afro-Americans (220),
followed by white-Americans (139), and the lowest in Asian-Americans (75) [24].
Pursuant to the data of the CDC-National Program of Cancer Registries and National Cancer
Institute Surveillance, Epidemiology and End Result Program in the USA, the incidence of PCa in
2014 was around 100 for all races, 50 for the Asians living in the USA, 90 for white-Americans and
150 for Afro-Americans.
PCa incidence in Asia is 50–100 times lower than in western countries. Pursuant to the data of
WHO from 2012, PCa incidence in Asia was 10.5% [36]. The lowest incidence measured was in rural
China (2.6) and in North Korea and Mongolia (2–3), while in Japan, it was 31 [37]. PCa incidence with
the inhabitants of Shanghai was 26 times lower than with Americans [35]. Asians migrating to other
countries show very fast the same epidemiological pattern. The risk of PCa development grows within
the first generation of immigrants from Japan and China to the USA, probably for their transition to
the western style of dieting [38,39].
Genetic factors are very important in PCa development: if the father had PCa, the son’s risk is
2× higher; if both father and brother had PCa, the risk is even 5 times higher [40]. A significant number
of PCas are caused by inflammation caused by infection, nutrition or other agents. Western diet, which
involves high intakes of red meat, fat, and low intake of plant foods, is one of the reasons for the highest
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PCa incidence in the West [41]. Obesity is an important risk factor for PCa. In obese men, there is an
increased concentration of E2, insulin, free IGF-1, and leptin in serum, and a reduced concentration
of free T and adiponectin. Although serum leptin levels are elevated, there is resistance to leptin in
obese people. The leptin from adipose tissue is thought to play a role in the development of advanced
PCa [42].
Androgens are essential for the development, growth, and survival of PCa. Castration is known to
lead to apoptosis of malignant cells and the decrease of PCa bone metastases. Like in normal prostatic
tissue, in PCa cells estrogens play an important role: activation of ERα stimulates proliferation, and
activation of ERβ leads to an antiproliferative and pro-apoptotic effect. Over time, loss of ERβ occurs
in PCa, leading to disease progression. Animal experiments show that PCa occurs in mouse strains
lacking the ERβ receptor (betaERKO), but does not occur in mice lacking the ERα receptor (alphaERKO).
Also, mice strains lacking the enzyme aromatase (ArKO) have a lower PCa incidence [43,44]. Therefore,
for PCa prevention, the blockage of ERβ is needed and ERβ stimulation.
Vitamin D has a protective effect on the development of PCa, and men with vitamin D deficiency
are known to have a higher PCa incidence. This category includes the elderly, people from the north
and African-Americans; in the latter, a large amount of melanin in the skin reduces the production of
active vitamin D. The vitamin D receptor, to which serum vitamin D binds, is present in the normal
and malignant prostate epithelium [45]. Normal prostate cells can make a synthesis of D vitamin, and
then, it inhibits their development [46].
2.5.1. Cellular Signaling Pathways in Prostate Cancer
Disorders at the level of cellular molecular signaling pathways play a key role in the development
of malignant tumors. In PCa, disturbances of the PI3K/Akt/mTOR signaling pathway are of great
importance [47]. The major proteins of this pathway are PI3K (Phosphatidylinositol 3-Kinase) and Akt
(Protein kinase B). The mTOR (mechanistic target of rapamycin) enzyme is named after rapamycin,
which inhibits mTOR and thus acts immunosuppressive and antiproliferative. The PI3K/Akt/mTOR
pathway regulates cell dormancy and proliferation and it is necessary for promoting the growth
and proliferation of adult stem cells. In many cancers, this pathway is overactive, due to increased
activity of PI3K, or Akt. Increased mTOR activity activates proliferation while decreasing tumor
apoptosis [48,49].
PI3K/Akt activity is enhanced by EGF, IGF-1, and insulin. On the other hand, the natural inhibitor
of PI3K/Akt, the enzyme PTEN (tumor suppressor phosphatase and tensin homolog), reduces the
activity of this pathway by interfering with PI3K and negatively affecting mTOR signals. One of the
most common reasons for mTOR activation is mutations or deletions in PTEN, which are present in
over 80% of PCa [50].
There are two complexes created by mTOR: mTOR complex 1 (MTORC1) and mTOR complex 2
(MTORC2). The MTORC1 is the most important regulator of cell growth, responding to and integrating
different signals from food and the environment; this complex is inhibited by rapamycin. The MTORC2
stimulates cell survival via Akt activation (Figure 2). Aberrant mTOR signals are responsible for the
development of many diseases.
The key genetic events in PCa progression are loss of functional androgen receptor (AR) and
increased expression of epidermal growth factor receptor, erbB. Genetic alterations lead to feedback
between the membrane receptor (erbB1) and the associated ligand (e.g., TGFα). The result is the
enhanced activation of the most important component for uncontrolled PCa growth, namely ERK1/2
(extracellular signal-regulated protein kinase 1/2) [51].
PCa resistance to therapy is associated with abnormally increased expression of AR, Bcl-2, erbB,
HER2 (human epidermal growth factor receptor 2), cyclin D1, and cyclooxygenase (COX-2), all of
which are associated with the activation of transcription nuclear factor NF-κB. The NF-κB is a protein
complex that controls DNA transcription, cytokine production, and cell survival. NF-κB is found in
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the cells of almost all animals and is involved in the cellular response to stress, cytokines, free radicals,
heavy metals, ultraviolet radiation, oxidized LDL, as well as bacterial and viral agents [52].Molecules 2019, 24, x FOR PEER REVIEW 7 of 33 
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2.5.2. In Vitro and In Vivo Experiments on Prostate Cancer
Human prostate adenocarcinoma cell lines, such as LNCaP, DU-145, and PC-3, are most commonly
used in in vitro experiments. Androgen-dependent lines are LNCaP, obtained from PCa metastases
to lymph nodes and 22Rv1. Androgen-independent lines are DU-145 and PC-3, which have no AR
and have ER. Animal experiments are most commonly performed on specific strains of mice and rats,
such as TRAMP (transgenic adenocarcinoma of the mouse prostate), betaERKO (mice lacking the ERβ
receptor), alphaERKO (mice lacking the ERα receptor), and ArKO (mice lacking aromatase). A nude
mouse is a laboratory mouse of the thymus-free variety that has an inhibited immune system due to
reduced T-cells. He got his nickname because he has no hair. This variety of mice can receive different
tissues and tumor grafts, without rejection [44].
2.6. Prostatitis
Prostatitis is the most common urological diagnosis in people under 50 and the third most common
urological diagnosis in people over 50 years, after BHP and PCa. The overall prevalence of chronic
prostatitis and chronic pelvic pain syndrome is 7.1%. However, the prostate inflammation is seen
in as many as 44% of the prostate tissue samples at autopsy, and even in individuals who have not
had prostate disease. Acute bacterial prostatitis is a prostate infection, most commonly caused by
gastrointestinal gram-negative bacteria. The risk factors for prostatitis are intraprostatic ductal reflux,
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phimosis, indwelling urethral catheter, transurethral surgery, and secretory prostate dysfunction.
Secretory dysfunction is accompanied by decreased levels of fructose, citric acid, acid phosphatases,
Zn, Mg, and Ca and an increase in pH, levels of inflammatory proteins and LDH-5 / LDH-1 ratio [53].
3. Polyphenols
3.1. Occurrence in Nature
Polyphenols are the most abundant and most examined secondary metabolites in the plant
kingdom, with over 8000 species known, but are still an area of research that claims many scientists [54].
Polyphenols play a key role in the growth, regulation, and structure of plants and vary between
different species. Stress and growth conditions modify the structure and content of polyphenols [55].
About 2% of all carbohydrates created during photosynthesis are converted to flavonoids and their
derivatives [56]. Polyphenols are found in a large number of plants, such as vegetables (artichokes,
cabbage, broccoli, asparagus, avocado, beetroot, and spinach), nuts (nuts, hazelnuts, pistachio, almonds,
Indian nuts, peanuts, pecans, and macadamia), dark pigmented fruit (cranberry, blueberry, plums,
blackberries, raspberries, strawberries, currants, figs, cherries, guava, oranges, mangoes, grapes, and
pomegranate), spice plants (cloves, cinnamon, oregano, cumin, turmeric, parsley, basil, curry powder,
mustard seeds, ginger, pepper, chili powder, pepper, garlic, coriander, onion, and cardamom), and
medical herbs (sage, thyme, marjoram, tarragon, mint, oregano, salty basil, and dill) [57,58].
The average daily intake of polyphenols in the European countries differs a lot: it is the highest
in Denmark (1700 mg) and the lowest in Greece (660 mg). The majority of ingested polyphenols are
phenolic acids (~55%), and in some regions, flavonoids (50–60%). The most important sources of
polyphenols in foods are coffee, tea, and fruits [59].
3.2. Classes of Polyphenols
All plant phenol compounds originate from amino acids phenylalanine, i.e., silimatic acid.
Silimatic pathway is a metabolic pathway, one of seven steps used by bacteria, fungus, algae, and the
bio-synthesis of plants for flavonoids and aromatic amino acids, while animals and people must intake
them through food. Polyphenols are classified in a number of ways, usually based on the number of
phenolic rings and they also contain the elements binding these rings to each other. The major classes
of polyphenols are flavonoids, phenolic acids, stilbenes, and lignans. Polyphenols can also be divided
into flavonoids and non-flavonoids [60,61].
3.3. The Action of Polyphenols in the Body
The antioxidant properties of polyphenols have been demonstrated in vitro, in numerous
experiments on isolated cell cultures; on the other hand, but a much larger problem is to prove
these properties in vivo. In addition to its direct antioxidant effect, polyphenols also act indirectly in
humans by increasing the level of uric acid. However, the “antioxidant hypothesis” does not offer
precise answers to understand the molecular mechanisms behind the beneficial effects of polyphenols
from food. Yet, the signaling effects of polyphenols are thought to occur at much lower concentrations
than those required for antioxidant activity [62,63].
The second effect of polyphenols is the modification of cellular signals and the regulation of
the action of various enzymes, such as PI3K, Akt/protein kinase B, tyrosine kinase, protein kinase C,
mitogen-activated protein kinase, etc. Signal effects of polyphenols probably appear with a lot lower
concentrations from the ones needed for antioxidant activity. In accordance with this, the “antioxidant
hypothesis” does not offer true answers for the understanding of molecular mechanisms that are in the
background of favorable polyphenol effects from foods. Also, another important effect of polyphenols
is to increase the secretion of paraoxonase, an enzyme that prevents low-density lipoprotein (LDL)
oxidation [64,65].
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3.4. Resorption of Polyphenols from Foods
The debate regarding the absorption of polyphenols from food is still ongoing. On the one hand,
epidemiological studies agree that there are positive health effects of taking polyphenols; on the
other hand, there is a low bioavailability of polyphenols in the body, due to low resorption and rapid
transformation and excretion. The absorption of polyphenols via the stomach and small intestine
is only 5–10% of the total intake. To be absorbed, polyphenols must be chemically transformed by
the intestinal microflora (“microbiota”) and enzymes from the intestinal epithelium. The absorption
of polyphenols depends on the amount and size of the phenolic compound, previous diet, nutrient
matrix, sex, and gut microflora [66,67].
The accurate assessment of the physiological effects of polyphenols from foods is very complicated
because single foods often contain a lot of different polyphenols, whose outcome is impossible to track
and measure. For example, there are about 60 different flavonoids in red wine. On the other hand,
mixtures of different polyphenols can have a synergistic and antagonistic effect. Also, polyphenols
effect antagonistically in the presence of vitamin C. The more powerful a polyphenol is, an antioxidant
regenerates faster, while the weaker antioxidants are spent [68,69].
3.5. Flavonoids
Flavonoids belong to the class of low molecular weight phenolic compounds and are widespread
in the flora world. They got their name from the Latin word flavus, which means yellow. Flavonoids are
found in large quantities in fruits and vegetables and drinks such as tea, cocoa, and wine. Today,
there are about 6000 flavonoids, which are mostly found as multicolored pigments of fruits, vegetables,
and medicinal plants [70].
The antioxidant activity of free flavonoids depends on the number and position of their hydroxyl
groups. The basic structure of flavonoid compounds is the flavone nucleus, which consists of two
benzene rings (A and B) that are linked via a heterocyclic pyran C ring. The position of the benzenoid
B ring is the basis for dividing the class of flavonoids into flavonoids (2-position) and isoflavonoids
(3-position) [71].
The average intake of flavonoids in the USA adults is about 250 mg per day, with flavan-3-ols
accounting for 80% of total intake. Tea is the main primary source of flavonoids and accounts for 80%
of the intake of all flavonoids. In Korea, the average daily intake of flavonoids is about 110 mg [72,73].
The main sources of flavonoids are in bio-kimchi (the Korean food of fermented vegetables), green tea,
Japanese apples, and soya.
The medical use of flavonoids is based on their antioxidant, anti-inflammatory, and anticarcinogenic
properties and their capacity to modulate key enzymatic functions in the cell. They are strong inhibitors
of enzymes such as xanthine oxidase, cyclooxygenase, lipoxygenase, and PI3-K. The primary role of
flavonoids in plants is to protect them from UV radiation, living or inorganic stress, etc. In the food
industry, flavonoids are added to foods to prevent fat oxidation.
There are numerous classifications of flavonoids. According to the degree of oxidation of the
central piran ring, flavonoids can be divided into six classes: 1. flavones, 2. flavonols, 3. flavanones, 4.
isoflavonoids, 5. flavan-3-ols (monomers and oligomers), and 6. anthocyanins.
3.5.1. Flavones
Flavones are widely represented in leaves and flowers. The most important sources of flavones
are celery, parsley, red pepper, chamomile, mint, and ginkgo biloba. Their well-known representatives
are luteolin, apigenin, and tangeretin (Figure 3).
Han (2018) found that luteolin inhibited PC-3 cell proliferation, migration, and cell renewal [74].
Apigenin showed similar activity on LNCaP and PC-3 lines. In a study in TRAMP mice, apigenin
was shown to suppress PCa formation via the PI3K/Akt/FoxO signaling pathway. There was a
decrease in tumor size and disappearance of distant metastases in TRAMP mice which received
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apigenin for 20 weeks [75]. Tangeretin induced epithelial–mesenchymal transition in PC-3 cells, via
the PI3K/Akt/mTOR signaling pathway [76].Molecules 2019, 24, x FOR PEER REVIEW 10 of 33 
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Quercetin s largely found in red grapes, red ine appl s, tea, and b ries. The highest
concentration of quercetin is fo n in canne ca ers ( 170 mg/100 g) and red onions (33 mg/100 g).
Quercetin acts as an antioxidant, as protein ki ase inhibitor and ctivator of ERα and ERβ. The action
of quercetin is three times weak r than E2; owever, it is nine times more elective for ERβ, than for
ERα [77]. The FDA states that quercetin is ne ther an antioxidant, nor a deficient nutrie t, nor a cure
for a y dise se in huma s. Nevertheless, Pa ler (2015) found that in African Americans with vitamin
D defic ency increased the intake of quercetin leads to a decreased risk of PCa. Sun (2018) states that
quercetin in combination with metform n inhibits growt , migration and invasion on PC-3 a d LN aP
cells by strongly inhibiting the VEGF/Akt/PI3K signaling pathway [78,79].
Fisetin is found in apples, grapes, kiwi, strawberries, oni s, and cucumber. On the PCa cell lines,
fisetin has been show to act as a dual inhibitor of PI3K/Akt and mTOR metabolic pathways. This is an
important finding, as mTOR activation is a lot more com on in tu ors with high PI3K/Akt expression.
It is believed that fisetin could be probably used in the treatment of PCa, alone or in combination with
chemotherapeutic drugs [47].
Kaempferol showed cytotoxicity across different cancer cell lines including Du145; it is offered as
a potential anticancer agent [80].
3.5.3. Flavanones
Flavanones are present in citrus fruits, oranges, lemons, and grapes. The most well-known are
hesperetin, naringenin, and eriodictyol (Figure 5).
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Hesperetin inhibits proliferation and induces cell cycle arrest in PC-3 cells, in the G1 phase.
Similarly, naringenin, natural flavonoid from grapefruit, and fruit, inhibits proliferation and migration
and induces ROS production and apoptosis on PC3 and LNCaP cells. Naringenin has been shown to
enhance the effect of paclitaxel on reducing progression in PCa lines [81,82].
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in Asia [84]. Except in soya, genistein and daidzein are also found in beans, peas, legumes, and 
peanuts, but in significantly smaller quantities. 
In soybean flour, the level of genistein is lower than genistin about 50 times, but only two times 
in fermented soya products. Specifically, during microbial fermentation, the beta-glycosyl bond of 
genistin is cleaved and genistein is formed [85]. A fermentation-like process occurs in the jejunum, in 
the intestinal wall, where the biologically inactive forms are hydrolyzed by the action of bacterial 
enzymes, β-glucosidases, and converted to biologically active aglycones, daidzein and genistein, 
which can be absorbed by intestines. The intestinal flora can convert daidzein into several products, 
including isoflavonoids equol and dihydrodaidzein. Interestingly, only 33–50% of people have a 
suitable bacterial strain that can produce the estrogen metabolite equol. These individuals, called 
“equol producers,” have more abilities to get estrogenic effects from soya. After their intake, the 
highest serum isoflavone values appear after 4–6 h, have a half-life of 4–8 h, and almost all isoflavones 
are excreted after 24 h [86,87]. 
The average daily isoflavonoid intake ranges 0.3–0.8 mg in Europe and the USA and 50–100 mg 
in Asia. Vegetarians and vegans in Europe consume an average of 22 mg of food isoflavones and 50 
mg of supplements. In some epidemiological studies, it was determined that an average daily intake 
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3.5.4. Isoflavonoids
Isoflavonoids are a large and inhomogeneous group of flavonoids. Isoflavonoids are derived
from the flavonoid biosynthesis pathway, via liquiritigenin or naringenin. In plants, they play a role
in the formation of phytoalexins during defense against germs. The most important isoflavonoids
belong to the subgroup of isoflavones and these are genistein, daidzein, and glycitein (Figure 6) and
their glycosides, genistin, daidzin, and glycytin. Unlike flavonoids, in which the benzenoid B ring
is in position 2, in the isoflavonoids the B ring is in position 3. The chemical structure of genistein
and daidzein is very similar to 17b-estradiol, E2 (Figure 6). These two isoflavones are also similar to
each other and differ in only one hydroxyl group, and share a common diphenolic structure. Genistein
competes with E2 for binding to the ER; however, genistein has more than 300-fold higher binding
affinity for ERβ than for ERα [83].
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The largest source of isoflavones in nature is soya, which contains about 200 mg of isoflavones
per 100 g of fresh product. Genistein and genistin make 30–60% of total soya isoflavones, daidzein,
and daidzin 40–60%, while glycitein and glycitin make 1–13% of total soya isoflavones. Genistin and
daidzin in soya are in conjugated form with sugars, as glycosides. Glycosides are converted into active
forms, genistein, and daidzein, by fermentation, which is the traditional way of preparing soya in
Asia [84]. Except in soya, genistein and daidzein are also found in beans, peas, legumes, and peanuts,
but in significantly smaller quantities.
In soybean flour, the level of genistein is lower than genistin about 50 times, but only two times
in fermented soya products. Specifically, during microbial fermentation, the beta-glycosyl bond of
genistin is cleaved and genistein is formed [85]. A fermentation-like process occurs in the jejunum,
in the intestinal wall, where the biologically inactive forms are hydrolyzed by the action of bacterial
enzymes, β-glucosidases, and converted to biologically active aglycones, daidzein and genistein,
which can be absorbed by intestines. The intestinal flora can convert daidzein into several products,
including isoflavonoids equol and dihydrodaidzein. Interestingly, only 33–50% of people have a
suitable bacterial strain that can produce the estrogen metabolite equol. These individuals, called
“equol producers,” have more abilities to get estrogenic effects from soya. After their intake, the highest
serum isoflavone values appear after 4–6 h, have a half-life of 4–8 h, and almost all isoflavones are
excreted after 24 h [86,87].
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The average daily isoflavonoid intake ranges 0.3–0.8 mg in Europe and the USA and 50–100 mg in
Asia. Vegetarians and vegans in Europe consume an average of 22 mg of food isoflavones and 50 mg
of supplements. In some epidemiological studies, it was determined that an average daily intake
of isoflavones in Japan and China is up to 75 mg and even 150–200 mg in the traditional Japanese
diet [84,88,89]. In different studies, the average intake of genistein and genistin is estimated to be
roughly 8–12 mg daily and 30 mg daily.
The average plasma isoflavones concentration in Europeans is 0.01 µmol/L and around 0.6 µmol/L
in Japan [85,88]. Isoflavones are specifically concentrated in prostatic fluid, in a concentration several
times higher than in plasma, especially in people who consume soya products [90]. In prostatic tissue,
genistein levels were the lowest in PCa (8.4 ng/g) than in large volume BPH (8.8 ng/g), and the highest
in small volume BPH (20.9 ng/g tissue) [91].
Bioavailability of Isoflavones
Genistein, like all other bioactive phytochemicals, has two major disadvantages: low bioavailability
and high pleiotropy. The oral bioavailability of genistein is lower than that of genistin, due to its
poor solubility in water. The plasma concentration of genistein from food is much lower than the
concentration required for initiating an anticancer response in an experimental model. A significant
clinical effects of genistein can be expected when given at pharmacological doses of >100 µM/L and
weak effects when it is given at chemopreventive doses <1 µM/L. Pleiotropy is a phenomenon when a
compound acts at several levels in a cell and at the same time initiates several biochemical reactions;
the anticancer effects of genistein are probably the result of numerous synergistic mechanisms [92].
Estrogenic and Antiestrogenic Activity of Isoflavones
Isoflavones are called plant estrogens because of their structural similarity to human estrogens
and their mild estrogenic activity. Compared to physiological estrogens, isoflavones have only between
0.01% and 0.1% of E2 activity on the molar base. However, isoflavones exert physiological effects in
high serum concentrations. Studies have shown that the concentration of isoflavones in people who
eat soya is at the micromole level and in people who do not eat soya, at the nanomole level [93].
A very important characteristic of isoflavones is that they do not have the same binding affinity
for both estrogen receptors. Specifically, isoflavones have a much higher binding affinity for ERβ than
for ERα; the relative binding affinity of genistein for ERβ is 36% and for ERα, 5% [94]. In various
studies, it was determined that genistein has a 40- to 60-fold greater affinity for ERβ than for ERα, and
daidzein, 5-fold. However, the genistein–daidzein–equol mixture has much higher selectivity for ERβ
than for ERα (82.6), suggesting their potential synergistic interactions. Isoflavones activate ERα in, the
absence of circulating estrogens, but competitively inhibit it at high estrogen concentrations [95,96].
Kostelac and co-authors found that half-maximal effective concentration, EC (50) for ERα
activation, for E2, genistein, and daidzein, were 0.03 µM, 15 µM, and 300 µM, respectively. On the
other hand, the EC (50) for ERβ activation, for E2, genistein and daidzein, were 0.01 µM, 0.03 µM and
0.35 µM, respectively [97]. Receptors ERβ are predominant in the prostate; in benign and malignant
prostate cells, isoflavones mostly stimulate ERβ and therefore suppress cell proliferation and promote
differentiation [98].
Androgenic and Antiandrogenic Effects of Isoflavones
Isoflavones act on the enzymes 5-alpha reductase (5αR) and aromatase. Genistein inhibits 5αR
activity in prostate fibroblasts, at a high dose, with an IC (50) of 710 µM [99].
At high doses genistein also inhibits some of the enzymes involved in T synthesis, so it can act as
an antiandrogen. In the fetal murine testis, at a dose of 10 nM (corresponding to a dose of 100 mg/kg in
humans), genistein reduces the early synthesis of T, via an ERα-dependent mechanism [100]. In rats in
the pubertal stage, administration of genistein at a dose of 40 mg/kg was followed by a slight decrease
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in serum T, while a dose of 10 mg/kg had no effect on serum T. Interestingly, in castrated rats, genistein
exhibits pronounced androgenic activity in the prostate gland [101,102].
Isoflavones also act on the enzyme aromatase, or estrogen synthetase, which converts T to estradiol
(E2) and androsterone to estrone (E1) (Figure 7). Genistein increases aromatase activity in ovarian,
breast, and estrogen-dependent breast cancer cells, and may nullify the effects of anti-aromatase drugs
in these cells, which should be taken into consideration in patients taking tamoxifen [103,104].
Genistein and D vitamin synergistically inhibit prostate epithelial cell growth. The flow cytometry
showed that genistein induces arrest in the G (2) M phase, and vitamin D induces arrest in the G (1/0)
phase of the cell cycle [105].
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The Effects of Isoflavones on Prostate Cancer 
Genistein has been previously known to block cell cycle progression in the G1 phase and inhibit 
PSA expression in PCa cell lines. At a dose of 1.25–10 μg / mL, genistein reduced the growth of BPH 
and PCa in histoculture. Physiological concentrations of genistein can reduce the expression of AR, 
mRNA, and protein levels in androgen-sensitive LNCaP cells [106,107]. 
A large number of in vitro studies have proven that genistein inhibits the growth and metastatic 
activity of hormone-dependent and hormone-independent PCa, with an IC50 of 5–40 nM (2–10 
mg/mL). At doses ≤20 mM, genistein inhibits growth and induces apoptosis in LNCaP, DU-145, and 
PC3 lines. At 50 mM/L, genistein completely inhibits the expression of the androgen-responsive 
PART-1 gene in LNCaP cells [108–110]. 
Chiyomaru found that genistein inhibits cell growth on PC3 and DU145 by down-regulating the 
oncogenic HOTAIR (human gene located on chromosome 12) molecule and altering the expression 
of several micro-RNAs [111]. 
More recent studies show that phytoestrogens do not act on AR but reactivate ERβ, which is 
otherwise “dormant” during carcinogenesis; so, reduced expression of ERβ leads to the same effect 
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catenin), and PI3K/Akt (phosphoinositide 3 kinase/Akt) signaling pathways. Genistein works 
synergistically with adriamycin, docetaxel, and tamoxifen [92]. 
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The Effects of Isoflavones on Prostate Cancer
Genistein has been previously known to block cell cycle progression in the G1 phase and inhibit
PSA expression in PCa cell lines. At a dose of 1.25–10 µg / mL, genistein reduced the growth of BPH
and PCa in histoculture. Physiological concentrations of genistein can reduce the expression of AR,
mRNA, and protein levels in androgen-sensitive LNCaP cells [106,107].
A large number of in vitro studies have proven that genistein inhibits the growth and metastatic
activity of hormone-dependent and hormone-independent PCa, with an IC50 of 5–40 nM (2–10 mg/mL).
At doses ≤20 mM, genistein inhibits growth and induces apoptosis in LNCaP, DU-145, and PC3 lines.
At 50 mM/L, genistein completely in ibits the expressio of the androgen-responsive PART-1 gene in
LNCaP cells [108–110].
Chiyomaru found that genistein inhibits cell growth on PC3 and DU145 by down-regulating the
oncogenic HOTAIR (human gene located on chromosome 12) molecule and altering the expression of
several micro-RNAs [111].
More recent studies show that phytoestrogens do not act on AR but reactivate ERβ, which is
otherwise “dormant” during carcinogenesis; so, reduced expression of ERβ leads to the same effect
as androgen stimulation [112]. ERβ reactivation is accompanied by reduced expression of androgen
markers, such as PSA and PCA3, the androgen coactivator PDEF and the IGF-1 receptor. Thus,
activati n of ERβ leads to an anti-androgenic effect on PCa [113,114]. I fact, genistein and ERβ work
together to prevent PCa cell proliferation; genistein increases ER-β levels via reducing its promoter
methylation, while ERβ mediates the preventive action of genistein [115].
Spagnuolo summarized the molecular mechanisms of genistein action: action on caspases,
Bax (B cell lymphoma 2 (Bcl-2) -associated X protein), KIF20A (Bcl-2, kinesin-like protein 20A),
ERK1/2 (extracellular signal-regulated kinase 1/2), NF-κB (nuclear transcription factor κB), MAPK
(mitogen-activated protein kinase), IκB (inhibitor of NF-κB), Wnt/β-catenin (Wingless and integration
1 β-catenin), and PI3K/Akt (phosphoinositid 3 kinase/Akt) signaling pathways. Ge istein works
s nergistically with adriamycin, docetaxel, and tamoxifen [92].
Animal Experiments
At a dose of 1 mg/g, genistein reduces prostate weight in rats and inhibits the expression of key
cellular pathways. Kim believes that genistein at higher doses acts more as a tyrosine kinase receptor
inhibitor than via the ERβ receptor [116]. Yang has demonstrated that soya isoflavones inhibit prostate
hyperplasia and increase NO and NO synthase expression in rats [117]. Isoflavone-rich diets lead to a
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significant decrease in PCa growth and a decrease in the incidence of spontaneous PCa formation in
mice and rats. When PCa-implanted rats are given subcutaneous injections of genistein (50 mg/kg),
tumor growth is inhibited, which is not seen at doses appropriate to those in the human diet [118,119].
At massive doses of 250–1000 mg/kg, genistein decreases the expression of both AR and ER in the rat
prostate [120].
Human Studies in Healthy Persons and BPH Patients
Healthy men consumed portions of 400 mL of soy milk, with 54 mg of genistein and 34 mg of
daidzein. After eight weeks, no differences in E2, T, free T and SHBG (sex hormone-binding globulin)
concentrations were observed between the persons and the control group. The only difference was the
decrease in estrone concentration, in the milk-drinking group [121]. Busby showed no evidence of
genistein toxicity or changes in blood biochemical analyses in healthy men taking doses of genistein
up to 16 mg/kg body weight (over 1000 mg daily). The plasma half-life of genistein was 3.2 h and that
of daidzein was 4.2 h [122]. Hong measured isoflavone levels in normal human prostate and BPH
tissue after surgery. He found that the concentration of genistein in BPH was significantly lower than
in healthy prostate (65 ng/mL vs 87 ng/mL) [123]. Wong administered 40 mg of isoflavone daily, or
placebo to patients with BPH. The patients had excellent tolerance of isoflavones for 12 months, but
they experienced very mild clinical improvement. Serum T level did not change after 12 months of
isoflavone intake [124].
Human Studies in Prostate Cancer Patients
Numerous epidemiological studies have shown a lower incidence of PCa in Asia, where soya-based
foods make up a large proportion of the diet [125,126]. Based on these studies, it was hypothesized
that soya isoflavones may have a protective effect on PCa. This hypothesis is supported by the fact
that in the USA, the incidence of latent PCa is twice as high as in Japan, but, the incidence of clinically
manifest PCa is as much as 15 times higher, suggesting that there are some factors in Japanese men
slowing or delaying the development of clinically significant PCa [127]. A soya-based diet could be one
of these factors. Specifically, when migrating to the USA and changing their diet, Asians have the same
rate of PCa as other Americans, with the rate of illness correlating positively with immigration time.
Hawaii residents who are Japanese, consume soya products and have a lower risk of PCa [39,128].
In 1998, the results of a multinational study from 42 countries showed that the use of soya products
significantly reduced the mortality of PCa [129]. However, it is difficult to prove the therapeutic effect
of genistein on humans, due to the different study design, the small number of patients, the short
treatment period, and the lack of standardized active ingredient formulas [130]. In a 2014 meta-analysis,
two studies confirmed that there was a potential role of soy isoflavones on PCa reduction, but data
from other studies were inconsistent [131].
A meta-analysis of 11 different studies (2015) showed that high levels of genistein and daidzein
and elevated serum enterolactone concentrations were associated with a significantly reduced risk of
developing PCa [132]. Russo (2017) found that genistein use was associated with a decreased risk of
PCa. An incidental finding was that the use of lignans was associated with an increased risk of PCa
disease [133].
Jarred found significantly higher tumor cell apoptosis in patients taking 160 mg of isoflavone
extract before surgery, i.e., radical prostatectomy (RP) [134]. Fischer administered soy preparations
to patients with PCa with 300 or 600 mg of genistein and 150 or 300 mg of daidzein for 12 weeks.
He found a 32% decrease in serum DHT levels and mild estrogenic effects, such as changes in the chest,
or hot flushes [135]. DeVere White gave patients with PCa who refused active treatment, or relapsed,
an extract of 450 mg genistein +450 mg other aglycone isoflavones daily, for six months. A significant
decrease in PSA was observed in all patients [136].
Van Veldhuizen administered isoflavones, at a dose of 112 to 224 mg daily, to patients prior
to RP. After surgery, the values of serum T, E2, and expression of ERα receptors were compared in
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preoperative biopsied tissue and definitive histopathological findings. A mild decrease in serum T
level was observed in most patients. There was also a decrease in serum E2 as well as decreased
expression of ERα in tissue [137].
Jarrard gave patients before RP genistein, 600 mg daily. The patients also received a single dose
of 200,000 IU of vitamin D3, at the beginning of the research. The increased AR expression was
demonstrated relative to the placebo group. It was shown that vitamin D inhibited the proliferation of
the prostate epithelium, and genistein enhanced this effect by inhibiting the CYP24 enzyme, which is
responsible for the intracellular metabolism of vitamin D. Both genistein and vitamin D inhibited the
synthesis of important mediator of the inflammation in prostate, prostaglandin E2 [138].
3.5.5. Flavanols (Flavan-3-ols) or Catechins
Flavan-3-ols are found in large quantities in tea, wine, bananas, apples, blueberries, peaches, and
pears. These compounds include catechin, epicatechin, epicatechin-3-gallate, epigallocatechin and
epigallocatechin-3-gallate, proanthocyanidins, theaflavins, and thearubigins [139]. Chemical structures
of some flavan-3-ol derivatives are presented in Figure 8. Flavanols are divided into two subclasses: a)
monomers (like catechin) and b) oligomers (proanthocyanidins). The catechin (monomer) molecule
is a building block of polymers (proanthocyanidins) and higher-order polymers (anthocyanidins).
Catechin monomers, dimers, and trimers are colorless. Higher-order polymers, anthocyanidins, have
a red color and turn into tannins. Catechins are found in abundance in tea plants, cocoa plants,
chocolates, fruits, vegetables, and wine [140,141].
Molecules 2019, 24, x FOR PEER REVIEW 15 of 33 
 
        .        
    it  , t t e begi i  of the research.      
t  relative to the placebo group. It wa  shown that vitamin D inh bited the proliferation 
of the prostate epithelium, and genistein enhanced this ffect by inhibiting the CYP24 enzyme, which 
is responsible for the intrace lular metabolism of vitamin D. Both gen stei  and vitamin D inhibi ed 
the synthesis of important mediator of the inflammat on in prostate, prostaglandin E2 [138]. 
. . . l ls ( l - - ls) r t i s 
l - - ls r  f  i  l r  titi s i  t , i , s, l s, l rri s, c s,  
rs. s  s i l  t i , i t i , i t i - - ll t , i ll t i   
i ll t i -3-gallate, proanthocyanidins, theaflavi s, and thearubigins [139]. Chemical 
structures of some flavan-3-ol derivatives are presented in Figure 8. Fla anols are divided into two 
subclasses: a) monomers (like catechin) and b) ligomers (proantho yanidins). The cat hin 
(monomer) mole ule is a building bl ck of polymers (proanthocyanidins) and higher-order polymers 
(anthocyanidins). Catechin monomers, dimers, and trimers are colorless. Higher- rder polymers, 
ntho yanidi s, have a red color and turn into tanni s. Catechins ar  found in abundance in tea 
plants, cocoa plants, chocolates, fruits, vegetables, and wine [140,141]. 
 
Figure 8. Chemical structures of some flavan-3-ol derivatives. 
Monomers 
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epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG). All listed catechins are present in a 
high concentration in green tea (30–42%) and less, in black tea (3–10%) [142]. The positive effects of 
catechins on human health are likely due to the chelation of metal ions such as iron (Fe) and copper 
(Cu). The iron and phenolic compounds in the gut lumen during digestion, as well as Fe-chelating 
complexes between Fe and polyphenols, have been demonstrated [143,144]. Some authors believe 
that the intake of six cups of green tea a day inhibits the carcinogenesis of PCa. 
After digestion in the human digestive tract, the fate of the complex of low-molecular-weight 
phenolic compounds and proteins is not entirely clear. In an in vitro digestion model, Laurent found 
that about 44% of catechins and 85% of epicatechins disappear after two hours of intestinal 
incubation, probably due to their interaction with pancreatic enzymes [145]. 
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Monomers
The flavan-3-ol monomers are catechin, epicatechin (EC), epicatechin-3-gallate (ECG),
epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG). All listed catechins are present in a
high concentration in green tea (30–42%) and less, in black tea (3–10%) [142]. The positive effects of
catechins on human health are likely due to the chelation of metal ions such as iron (Fe) and copper
(Cu). The iron and phenolic compounds in the gut lumen during digestion, as well as Fe-chelating
complexes between Fe and polyphenols, have been demonstrated [143,144]. Some authors believe that
the intake of six cups of green tea a day inhibits the carcinogenesis of PCa.
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After digestion in the human digestive tract, the fate of the complex of low-molecular-weight
phenolic compounds and proteins is not entirely clear. In an in vitro digestion model, Laurent found
that about 44% of catechins and 85% of epicatechins disappear after two hours of intestinal incubation,
probably due to their interaction with pancreatic enzymes [145].
In Vitro Studies
Catechins from green tea cause cell cycle arrest and apoptosis in malignant cells; EGCG is the
most potent catechin that inhibits cell growth and causes apoptosis in human PCa lines. In addition,
EGCG was proven to inhibit the activity of the enzyme NO synthase [146–148].
Agarwal found that in DU145 cells genistein and EGCG caused inhibition of erbB1 membrane
receptor activation caused by TGFα. Silymarin, genistein, and EGCG caused inhibition of cell growth
at lower doses and complete growth inhibition at high doses [51]. Gupta has demonstrated that
EGCG-induced apoptosis in LNCaP cells is performed by two pathways: the first is the stabilization of
tumor suppressor gene p53 and the reduction of MDM2 protein expression; the second pathway is the
negative regulation of NF-jB activity, which leads to a decrease in the expression of the anti-apoptotic
protein Bcl-2. The p53 gene is the most commonly mutated gene in PCa and other human cancers.
NF-jB is a nuclear transcription factor that controls various immune responses, such as inflammation
and apoptosis [149,150].
In PCa cells, EGCG increases the expression of CDK inhibitors, such as p16, p18, p21, and the
expression of p53 gene. In addition, EGCG has been shown to stabilize the p53 gene and thus induce
apoptosis in LNCaP cells [150,151]. Moreover, it was demonstrated that EGCG induces gene expression
for 16 kinases and phosphatases in prostate cells, including the tumor suppressor gene (SHP-1) and
the prostatic acid phosphatase-producing genes [152].
On DU145 and LNCaP cell lines, Siddiqui has demonstrated that EGCG causes induction of
apoptosis as well as cell cycle arrest in the G0/G1 phase [153]. On LNCaP cells, EGCG has been shown
to reduce PSA production; a decrease in PSA production was associated with the length of EGCG
administration [154].
Animal Studies
Liao inoculated cells from PC-3 and LNCaP 104-R (androgen-repressed) lines into nude mice.
Intraperitoneal injection of EGCG inhibited growth and rapidly reduced the size of human PCa in nude
mice [155]. Kao reported that plasma T concentrations decreased by 70% in EGCG treated mice [156].
Hipaka showed in 2002 that EGCG and ECG inhibit 5αR activity in rats [157]. In guinea pigs receiving
catechin, quercetin, and resveratrol, aortic fat reduction of 84%, 80%, and 76%, respectively, was found
compared with the control group [158].
Human Studies
Tea polyphenols are partially resorbed from the intestinal tract so that they can exert effects not
only in the gut but throughout the body [159]. Numerous epidemiological studies have shown that
Japanese and Chinese inhabitants who regularly drink tea have a lower incidence of PCa, and that the
risk of PCa decreases with increasing frequency, duration, and amount of green tea drinking [160].
Jain has shown that people in Canada who drink over two cups of tea a day have a lower incidence of
PCa [161].Yang found that after taking 1.5 g of green tea dissolved in 500 mL of water, the maximum
plasma concentration (Cmax) of EGCG was 326 ng/mL, EGC, 550 ng/mL, and EC, 190 ng/mL. When the
dose was increased to 3.0 g, Cmax increased three times. The half-life of EGCG (5.0–5.5 h) was higher
than the half-life of EGCG or EC (2.5–3.4 h) [162]. Catechin levels in saliva after drinking a green tea
were significantly higher than in plasma, but with a shorter elimination half-life than in plasma, of
10–20 min. The catechin concentrations in saliva were: EGC; 11.7–43.9 µg/mL, EGCG; 4.8–22 µg/mL,
and EC; 1.8–7.5 µg/mL. However, keeping the tea in the mouth for several minutes without ingestion
caused higher concentrations of catechins in saliva and EGC in urine. These results suggest that EGCG
is converted to EGC in the oral cavity and that both catechins are absorbed through the oral mucosa.
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Slow drinking of tea is important for catechin intake [163]. Pisters found that a dose of 1.0 g/m2
green tea extract, three times a day, was well tolerated and did not cause side effects. This dose was
equivalent to 7–8 Japanese cups of 120 mL green tea [164].
However, in a major European study (2018), involving 140000 subjects over a 14 year period, no
relationship was found between coffee and/or tea consumption and the risk of PCa [165].
Oligomers
Proanthocyanidins are blue and purple pigments found in numerous plants. A large number
of these compounds are dimers of epicatechin (procyanidin A1, procyanidin A2) and oligomers of
catechins and epicatechins and their esters with gallic acid. Proanthocyanidins are found in a large
number of plants, such as apple, cinnamon, aronia, coconut, grapes and grape products, blueberries,
cranberries, black currants, and green and black tea. The highest amount of proanthocyanidins is
found in chocolate and apple (165 mg and 147 mg, per serving), significantly higher than in red wine
and cranberry juice (22 mg and 32 mg per serving) [141].
Since the discovery of “French Paradox”, polyphenols from grapes and wine have attracted
the attention of scientists. The average concentration of polyphenols in certain parts of the grapes,
expressed as gallic acid equivalent (GAE) is: in seeds 2180 mg/g, in skin 375 mg/g, in leaf 350 mg/g and
in “meat”, i.e., the juicy part, only 24 mg/g [166].
Some phenolic compounds in grapes are bioavailable, while compounds composed of large
molecules are not, because they cannot be absorbed [167]. Of the phenolic compounds, the grapes
contain mainly flavan-3-ols, flavonols, anthocyanins, stilbenes, and phenolic acids. About 60–70%
of polyphenols in grapes are present in grape seeds, as procyanidins, that is, as dimers, trimers and
other oligomers of flavan-3-ols [168]. Flavan-3-ols are present in large quantities in white grapes, while
pigments, and anthocyanins, are mainly found in the skin of red grapes. Both catechin monomers and
dimers have a high antioxidant capacity [169,170].
In Vivo Studies
Kaur found that grape seed extract (GSE) had a higher antioxidant capacity than vitamins C
and E. At a concentration of 100 mg/L, GSE inhibited superoxide anion and hydroxyl radical by
about 80%, which was significantly higher than with vitamin C (~15%) and vitamin E (~40%) [171].
In DU145 cells, commercial GSE extract with 95% procyanidins, induced apoptosis and inhibited
the EGFR-Shc-ERK1/2-Elk1-AP1 signaling pathway [172,173]. Singh demonstrated that GSE had
anticancer activity against hormone-refractory PCa (HRCaP) [174]. Schmidt found that blueberry
proanthocyanidins inhibited the growth of LNCaP cells [175]. Baud demonstrated that GSE inhibits
the NF-kB pathway and thus induces apoptosis in DU145 cells [176].
After two hours of incubation in vitro, the monomers and dimers were stable in the intestinal
medium at pH 7; dimer degradation began at pH 7.4 and all dimers disappeared at pH 8.5. At pH 7.5,
after two hours of incubation, 15–34% of epicatechins underwent degradation while catechin was
stable [177]. In an in vitro digestion experiment, Argyri showed that red wine reduced the concentration
of digested phenolic compounds, due to the formation of Fe-polyphenolic chelates. Also, consuming red
wine reduces the oxidative stress induced by Cu-oxidized LDL and increases the concentration of HDL
cholesterol; similar to wine, grape juice also inhibits Cu-induced oxidation of human LDL [178,179].
Animal Studies
Chokkalingam has demonstrated that GSE increases the level of insulin-like growth factor binding
protein-3 (IGFBP-3), which can influence the suppression of PCa growth. DU145 cells were implanted
to nude mice; after seven weeks of feeding with GSE, there was a decrease in the proliferation index
and an increase in the apoptosis index, as well as a decrease in tumor size. GSE strongly inhibited the
secretion of vascular endothelial growth factor (VEGF) and strongly increased IGFBP-3 production in
the tumor [180].
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Human Studies
Grape polyphenols are rapidly absorbed into the plasma, reaching a maximum concentration
2–3 h after ingestion [181]. After two weeks of daily consumption of red wine (375 mL), an increased
concentration of phenolic compounds in the plasma was recorded [182].
Polyphenols from red wine and grape juice inhibit LDL oxidation and increase HDL concentration,
which reduces the risk of atherosclerosis and coronary heart disease. Grape polyphenols also have
a beneficial effect on diabetes by improving insulin resistance. Moderate and regular consumption
of red wine reduces the risk of type 2 diabetes by 30% [183–185]. In a 2013 review, Vance stated that
coffee and tea provide protection against advanced PCa. Lycopene seems to reduce a disease risk of
PCa, while selenium, vitamin C, and beta-carotene do not have such evidence. Regarding vitamin E,
alpha-tocopherol potentially increases the disease risk from PCa, and gamma-tocopherol reduces
it [186].
3.5.6. Anthocyanins
Anthocyanins (anthos = flower, kianeos = dark blue) are water soluble pigments that, can be red,
blue, or purple, depending on pH. About 2% of all hydrocarbons generated during photosynthesis are
converted to flavonoids and their derivatives, such as anthocyanins, which have antioxidant properties
and provide protection against ultraviolet radiation and cold [187].
Anthocyanin analogs without sugar are called anthocyanidins. Anthocyanins are found in all
tissues of higher plants, especially in fruits, flowers, and leaves. They are mainly found in fruits such as
cranberries, black currants, red and merlot grapes, strawberries, blackberries, blueberries, raspberries,
cherries, red apples, red peaches and vegetables, like eggplant, black rice, and red cabbage [188].
The highest concentrations of anthocyanins per 100 g of fruits are found in the shell of black
soybean (2000 mg), aronia (1480 mg), red grapes (888 mg), and blue eggplant (750 mg) [189,190]. Today,
200 different anthocyanins are known; only in red grapes, there are over 15 anthocyanins. The most
common anthocyanins in nature are cyanidin, delphinidin, malvidin, pelargonidin, and peonidin
(Figure 9), in the form of glycosides.
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anthocyanin in the diet is cyanidin-3-O-β-glucopyranoside (C3G), especially abundant in red orange 
juice. The anti-proliferative effect of C3G via activation of caspase-3 and induction of p21 protein 
expression in two different lines, LNCaP and DU145, has been demonstrated [192]. In another study, 
the anthocyanin treatment of DU-145 cells resulted in a significant increase of apoptosis and a 
significant decrease in p53 and Bcl-2 expressions and also a significant decrease in PSA and AR 
expressions. In addition, the anthocyanin treatment significantly inhibited tumor growth in the 
xenograft model [193]. 
Anthocyanins are poorly absorbed in the human gastrointestinal tract, and massively 
metabolized by the intestinal microflora into several metabolites, such as phenolic acids 3-O-methyl-
gallic (Megal), gallic (Gal), syringic, vanillic, and protocatechuic acid. The digestion of anthocyanins 
into the colon is completed six hours after their administration. Megal and Gal are effective in 
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In the wine, malvidin-3-glucoside has the highest antioxidant capacity [191]. The most abundant
anthocyanin in the diet is cyanidin-3-O-β-glucopyranoside (C3G), especially abundant in red orange
juice. The anti-proliferative effect of C3G via activation of caspase-3 and induction of p21 protein
expression in two different lines, LNCaP and DU145, has been demonstrated [192]. In another study,
the anthocyanin treatment of DU-145 cells resulted in a significant increase of apoptosis and a
significant decrease in p53 and Bcl-2 expressions and also a significant decrease in PSA and AR
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expressions. In addition, the anthocyanin treatment significantly inhibited tumor growth in the
xenograft model [193].
Anthocyanins are poorly absorbed in the human gastrointestinal tract, and massively metabolized
by the intestinal microflora into several metabolites, such as phenolic acids 3-O-methyl-gallic (Megal),
gallic (Gal), syringic, vanillic, and protocatechuic acid. The digestion of anthocyanins into the colon is
completed six hours after their administration. Megal and Gal are effective in reducing the vitality of
colon cancer cells. Anthocyanins from wine and grapes inhibit phosphodiesterase-5 activity, lead to
vasorelaxation and thus reduce the risk of cardiovascular diseases [194–196].
Although the effects of anthocyanins have been demonstrated in vitro, there is no reliable evidence
that anthocyanins act as antioxidants after consuming these plants. The fate of anthocyanins in vivo
shows that they are poorly conserved and that most of the chemically modified metabolites are rapidly
excreted. However, a 2019 study proved that the administration of anthocyanins caused an increase in
organ antioxidant capacity in animal models [197].
The results of a 20 year study (2012) showed that high anthocyanin intake reduced the risk of
T2D [198,199].
3.6. Phenolic Acids
3.6.1. Hydroxybenzoic Acids
Gallic acid (GA) is naturally found in grapes, tea, hops, and oak bark. In nature, GA is free
or as a part of soluble tannins. Gallic acid produces dimers, such as ellagic acid (EA) (Figure 10).
During hydrolysis, the soluble tannins break down into GA and glucose (gallotannins), or to EA
and glucose (ellagitannins). Plants produce EA by the hydrolysis of tannins, such as ellagitannin.
In humans, EA derivatives are processed in the intestine by the action of the intestinal microflora to
form urolithins (Figure 9). The largest amount of EA is found in nuts, berries, grapes, peaches, and
pomegranates, while ellagitannins are most common in fruits and leaves of raspberries, blackberries,
blueberries, nuts, and red grape [200,201].
Molecules 2019, 24, x FOR PEER REVIEW 19 of 33 
 
reducing the vitality of colon cancer cells. Anthocyanins from wine and grapes inhibit 
phosphodiesterase-5 activity, lead to vasorelaxation and thus reduce the risk of cardiovascular 
diseases [194–196]. 
lthough the effects of anthocyanins have been demonstrated in vitro, there is no reliable 
evidence that anthocyanins act as antioxidants after consuming these plants. The fate of anthocyanins 
in vivo shows that they are poorly conserved and that most of the chemically modified metabolites 
are rapidly excreted. However, a 2019 study proved that the administration of anthocyanins caused 
an increase in organ antioxidant capacity in animal models [197]. 
The results of a 20 year study (2012) sho ed that high anthocyanin intake reduced the risk of 
T2D [198,199]. 
 li  i  
3.6.1. y roxybenzoic ci s 
allic aci  (GA) is naturally found in grapes, tea, hops, and oak bark. In nature, GA is free or as 
a part of soluble tannins. Gallic acid produces dimers, such as ellagic acid (EA) (Figure 10). During 
hydrolysis, the soluble tannins break down into GA and glucose (gallotannins), or to EA and glucose 
(ellagitannins). Plants produce EA by the hydrolysis of tannins, such as ellagitannin. In humans, EA 
derivatives are processed in the intestine by t e action of the intestinal microflora to for  urolithins 
(Figure 9). The largest amount of EA is found in nuts, berries, grapes, peaches, and pomegranates, 
while ellagitannins are most common in fruits and leaves of raspberries, blackberries, blueberries, 
nuts, and red grape [200,201]. 
 
Figure 10. Chemical structures of gallic acid, ellagic acid, and urolithin A. 
Kaur demonstrated that GA leads to apoptosis in DU145 and 22Rv1 cell lines. In nude mice fed 
with GA, tumor growth inhibition occurs [202]. It has also been shown that GA reduces survival, 
proliferation, and invasion in PC3 cells [203]. In a 2015 study, Park demonstrated the apoptotic effect 
of gallotannin in DU145 and PC-3 cell lines. In addition, gallotannin decreased the expression of some 
survival genes, such as Mcl-1.The inhibition of Mcl-1 and caspase activation are the key moments in 
PCa cell apoptosis, induced by gallotannin [204]. 
Dimeric ellagitannin, Enotein B, causes a decrease in LNCaP cell proliferation and reduction of 
BPH in rats. Enotein B is found in the willowherb (Epilobium angustifolium), which is used in 
traditional medicine to treat BPH and prostate inflammation [205]. In human volunteers who drank 
willowherb tea, only urolithin conjugates were found in urine. In a 2017 paper, Roberts examined the 
metabolism of ellagitannins (ET) in humans. In the usual diet, the average daily intake of polyphenols 
was about 1250 mg, and coffee and tea were the main sources of polyphenols (1100 mg daily), and 
provided the intake of about 12 mg ET daily [206]. 
A significant amount of ET is found in pomegranate (Punica granatum). There is evidence that 
pomegranate has a positive effect on the treatment and prevention of diabetes, atherosclerosis, PCa, 
breast, colon, lung, and skin cancers [207,208]. 
Ellagitannins from pomegranate called punicalagin (PN) caused induction of apoptosis in PC-3 
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Kaur demonstrated that GA leads to apoptosis in DU145 and 22Rv1 cell lines. In nude mice
fed with GA, tumor growth inhibition occurs [202]. It has also been shown that GA reduces survival,
proliferation, and invasion in PC3 cells [203]. In a 2015 study, Park demonstrated the apoptotic effect
of gallotannin in DU145 and PC-3 cell lines. In addition, gallotannin decreased the expression of some
survival genes, such as cl-1.The inhibition of cl-1 and caspase activation are the key moments in
PCa cell apoptosis, induced by gallotannin [204].
Dimeric ellagitannin, Enotein B, causes a decrease in LNCaP cell proliferation and reduction of
BPH in rats. Enotein B is found in the willowherb (Epilobium angustifolium), which is used in traditional
medicine to treat BPH and prostate inflammation [205]. In human volunteers who drank willowherb
tea, only urolithin conjugates were found in urine. In a 2017 paper, Roberts examined the metabolism
of ellagitannins (ET) in humans. In the usual diet, the average daily intake of polyphenols was about
1250 mg, and coffee and tea were the main sources of polyphenols (1100 mg daily), and provided the
intake of about 12 mg ET daily [206].
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A significant amount of ET is found in pomegranate (Punica granatum). There is evidence that
pomegranate has a positive effect on the treatment and prevention of diabetes, atherosclerosis, PCa,
breast, colon, lung, and skin cancers [207,208].
Ellagitannins from pomegranate called punicalagin (PN) caused induction of apoptosis in PC-3
and LNCaP cells [209]. In addition to ellagitannins, large amounts of anthocyanins are also found
in the pomegranate. Pomegranate fruit, as well as pomegranate juice, extract, and oil, have potent
antioxidant activity and antitumor properties in various tumors, including PCa [207].
Urolithins
Urolithins A and B are metabolites of the microflora of the colon produced by the intake of EC
derivatives. Sánchez-González (2014) has shown that foods rich in ET, such as nuts, can contribute
to the prevention of PCa. In the study, urolithins induced apoptosis in LNCaP cells and this effect
was correlated with a decrease in Bcl-2 protein levels. Urolithins most likely block the expression
of the androgen receptor (AR), and thus, leads to the induction of apoptosis and decreased PSA
synthesis [210].
3.6.2. Hydroxycinnamic Acids
Chemical structures of the most important hydroxycinnamic acids are presented in Figure 11.
Caffeic acid is found in burdock, hawthorn, artichoke, pear, apple, oregano, basil, and thyme.
Caffeic acid and its natural ester-caffeic acid phenethyl ester (CAPE) are potent inhibitors of
the androgen-dependent PCa lines [211]. Liu demonstrated that caffeic acid and CAPE from bee
propolis [212] suppressed tumor growth and Akt signals in human PCa cells and showed a synergistic
effect with chemotherapeutics and external radiation [213]. Cinnamic acid is found in the aloe
plant. Esters of cinnamic acid strongly inhibit the growth of prostate and breast cancer by inducing
apoptosis [214]. Chlorogenic acid is found in Echinacea, strawberries, pineapple, coffee, sunflower, and
blueberries. In the animal model, chlorogenic acid inhibits BPH growth, probably via inhibition of
5αR [215]. Ferulic acid is found in oats, rice, artichokes, oranges, pineapples, apples, and peanuts. In a
2015 paper, Eroglu demonstrated that ferulic acid caused cell cycle arrest in PC3 cells and apoptosis in
LNCaP cells [216].
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3.7. Stilbenes
Resveratrol (Figure 12) is a powerful antioxidant found mainly in grapes and red wine, and in berries
and onions. The poor hydro-solubility and bioavailability of resveratrol are limitations of its clinical use.
Cheng (2017) found that resveratrol can induce nuclear accumulation of COX-2 (Cyclooxygenase-2) and
thus enhance p53-dependent inhibition of antiproliferation in cancer. The enzyme COX-2 is involved in
the development of cancer. Treatment of LNCaP cells with resveratrol led to the phosphorylation and
the nuclear translocation of ERK1/2 (mitogen-activated protein kinase) and the accumulation of nuclear
COX-2 and subsequently to the complex formation with pERK1/2 and p53 [217].
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Saralkar (2017) believes that resveratrol will be able to be used in nanoparticles in the future. In fact,
hydrophobic medicines can be “trapped” in nanoparticles, such as Ca-alginate. Nanoparticles filled
with medicines have had a cytotoxic effect on the cells of DU-145. It is believed that the nanoparticles
with Ca-alginate could probably be given intravenously [218].
3.8. Lignans
The highest concentration of lignans is found in oilseed rape (20 µg/100 g) [219]. The most
important plant lignan, secoisolariciresinol diglucoside (SDG), is an antioxidant phytoestrogen found
in flax, sunflower, sesame and pumpkin seeds. In the human gastrointestinal tract, SDG is further
metabolized to secoisolariciresinol, enterodiol, and enterolactone (ENL) (Figure 13) [220].
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The flax extract has been shown to prevent the induced BPH in rats [221]. Ren (2016) showed that
enterolactone binds to G protein-coupled estrogen receptor 1 (GPER) and thus reduces the prostate
growth in rats. When estrogen binds to GPER, rapid, non-genomic signaling occurs in the cell [222].
De Amorim Ribeiro (2017) gave flax-based food to rats with induced BPH, for 20 weeks. The flax was
found to have a protective effect on prostate epithelium in previously induced BPH [223].
The evidence from preclinical and animal studies has demonstrated the anticancer action of flax
lignans, especially the action of enterolactone against PCa. However, after the ingestion of flax through
food, rapid metabolism of lignans occurs, so that only glucuronic acid conjugates, which have modest
effects in vivo [224], considering the systemic circulation.
A recent Swedish study of 1010 cases during a mean follow-up of 14.6 years found that plasma ENL
concentration was positively associated with consumption of high-fiber bread, fruit, tea, and coffee,
while it was negatively associated with smoking and obesity. In subgroup of men with abdominal
obesity, the association between high ENL levels and lower odds of high-risk PCA was proved [225].
3.9. Curcumin
Curcumin (diferuloylmethane) is a consistent part of turmeric, a spice to give it the yellow powder
color of c rry (Figure 14).
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PCa resistance to a therapy is associated with the abnormally increased expression of Bcl-2, and
androgens receptor (AR), epidermal growth factor receptor (EGF), HER2 (human epidermal growth
factor receptor 2), cyclic D1, and cyclone-oxygenize (COX-2), and all of them are connected to the
activation of the transcription factor NF-kB. Nuclear factor-kB (NF-κB) is a protein complex and it
controls DNA transcription, cytokine production, and cell survival. NF-κB is placed in cells of almost
all animals and it is included into the cell answer to stress, cytokines, free radicals, heavy metals,
ultraviolet sunrays, oxidized LDL, and also to bacterial and virus agents [52].
The agent that can slow down these mechanisms would be good both for the prevention
and the treatment of PCa. Curcumin can modulate several of these ways. It has been shown that
curcumin to sublimates the proliferation of androgen-dependent lines, such as LNCaP, but also of
androgen-independent lines, such as DU145. Besides this, it has been shown for curcumin to increase
the sensitivity of cell cultures of PCa onto gamma-radiation. Curcumin reduces the trans-activation
and the expression of AR and it acts as its antagonist. Thus, curcumin reduces the expression of
receptors of EGF and induces the degradation of HER2. Curcumin reduces angiogenesis in vivo and
the expression of VEGF. The pathway of t PI-3K/AKT plays a critical role in the cell activation of CaP.
The phosphatase regulating this pathway, PTEN, is mutated with PCa and it leads to AKT activation
studies on the ability of curcumin to inhibit AKT activation AKT [226].
Mohebbati et al. have come to the facts by researching the data banks for curcumin as an inhibitor
of the tumor necrosis factor production (TNF-α) and prostaglandin E2 (PGE2), but it increases the
caspase activity (3, 8 i 9) in HL-60 prostate carcinoma. Besides this, we have found for curcumin to
sublimate vascular and endothelial growth factor (VEGF) in the line of carcinoma ovarium [227].
In a study in 2018, Chen examined the anti-carcinoma potential of curcumin analogs of the second
generation. The cells of PC3 and DU145 were treated in series of curcumin analogs, in concentrations
of 0–10 µM. It was found for curcumin to inhibit the expression of the nuclear factor (NF)-kB, mTOR
(mammalian target of rapamycin), AKT and p-AKT. For curcumin, it was found to have anti-carcinoma
effect against CRPC cells [228].
The aim of the investigation of Morabito and co-workers was to verify whether the different
concentrations of curcumin, conducted on human erythrocytes, may counteract Band 3-mediated anion
transport alterations due to oxidative stress. This study demonstrated that curcumin at a concentration
of 10 uM was very effective in protecting red cells from oxidative stress. [229].
In the paper in 2018, Ide et al. examined the effect of curcumin on the intracranial synthesis of
androgen in the cells of CaP, in the lines of LNCaP and 22Rv1. The tissue from the trans-gene
adenocarcinoma of the mouse prostate (TRAMP) was taken after one month of oral intake of
200 mg/kg/curcumin per day. Curcumin reduced the expression of steroid acute regulatory proteins
CYP11A1 and HSD3B2, and it confirmed a reduction of testosterone production. At the same time, it
confirmed the testosterone reduction in the prostate tissue of TRAMP mice. Simultaneously, curcumin
brought to the increased level of Aldo–Keto reduction 1C2 (AKR1C2), and it confirms reduced level of
dihydrotestosterone [230].
4. Conclusions
It is fascinating how much biochemical processes in plants are incorporated into the metabolism
of animal cells. However, this fact is logical, when we know how many billion years a common
microcosmos has existed in plant and animal cells. Herbivores have used plant nutrients in their diets
for eons. However, in addition to sugars, proteins, and fats, animals also ingest thousands of secondary
Molecules 2019, 24, 3982 23 of 34
plant metabolites, such as polyphenols. Polyphenols in plants play important roles such as protection
against herbivores, oxidative stress, UV radiation, etc. However, their roles in animal and human
organisms are much too complicated and plentiful to be completely understood.
There are a very large number of investigations on human cell cultures and animal models to
confirm the antioxidant and antitumor effects of polyphenols. In addition, extensive epidemiological
studies and centuries-old traditional folk experiences confirm the positive effects of polyphenols on
human health. However, the pathways of polyphenols in the human body are difficult to follow, due
to their relatively low resorption, the production of a large number of metabolites and relatively rapid
excretion from the body.
The future researches on the vast range of polyphenolic compounds in nature and their effects
on the human body will probably evolve towards increasing resorption and bioavailability, through
nanotechnology or other technologies. In the future, major randomized epidemiological studies will
provide more comprehensive answers to the questions of the role of polyphenols in human health.
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